Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Blinded Drug

13 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Prevention

    COGALTE1621

    10/03/2016

    Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

    Supportive Care

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCBMT16110

    03/10/2017

    A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCHEM1622

    03/02/2017

    A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions

    Treatment

    VICCBRE15147

    01/20/2017

    A Randomized Phase II Trial of Fulvestrant with or without Ribociclib (LEE011) After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Advanced Hormone Receptor Positive, HER2 Negative Breast Cancer

    Treatment

    ECOGNEUA221208

    01/18/2017

    Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis after Radiosurgery for Brain Metastases

    Treatment

    VICCBMT1567

    01/13/2017

    Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

    Treatment

    VICCBMT1695

    12/30/2016

    A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplant versus Placebo In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-cell Subtype

    Treatment

    VICCBRE1642

    12/15/2016

    Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

    Treatment

    VICCTHO15115

    11/08/2016

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumor Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

    Treatment

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Treatment

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Treatment

    VICCSAR1483

    02/26/2015

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas


    Print this page for your doctor